Online inquiry

IVTScrip™ mRNA-Anti-ALB&IL6R, 20A11-9mer-ALB11(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ351MR)

This product GTTS-WQ351MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets ALB&IL6R gene. The antibody can be applied in Inflammatory conditions, Systemic lupus erythematosus (SLE) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000477.7; NM_002190.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 213; 3570
UniProt ID P02768; P08887
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ALB&IL6R, 20A11-9mer-ALB11(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ351MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6408MR IVTScrip™ mRNA-Anti-PDCD1, CT-011(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA CT-011
GTTS-WQ10455MR IVTScrip™ mRNA-Anti-SOST, LY2541546(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA LY2541546
GTTS-WQ15060MR IVTScrip™ mRNA-Anti-KDR, SSS-23(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA SSS-23
GTTS-WQ1823MR IVTScrip™ mRNA-Anti-CFD, AFD Anti-fD(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA AFD Anti-fD
GTTS-WQ7670MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, GEN3013(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA GEN3013
GTTS-WQ14474MR IVTScrip™ mRNA-Anti-MAPT, RO-7105705(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA RO-7105705
GTTS-WQ12735MR IVTScrip™ mRNA-Anti-TIGIT, OMP-313M32(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA OMP-313M32
GTTS-WQ11285MR IVTScrip™ mRNA-Anti-hly, MEDI4893(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MEDI4893
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW